Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of LY2584702 in Participants With Advanced Cancer
A Phase I Study of LY2584702 in Patient With Advanced or Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
A Study of LY2584702 in Participants With Advanced Cancer
A Phase I Study of LY2584702 in Patient With Advanced or Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Advanced Image Guidance Utilized in Liver Surgery
Advanced Image Guidance for Ablation Probe Placement in Laparoscopic Liver Surgery: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Carolinas Health System
mi
from
Charlotte, NC
Advanced Image Guidance Utilized in Liver Surgery
Advanced Image Guidance for Ablation Probe Placement in Laparoscopic Liver Surgery: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Carolinas Health System
mi
from
Charlotte, NC
Click here to add this to my saved trials
Visually Enhanced Education About Prostate Cancer
Visually Enhanced Education About Prostate Cancer (VEEP-C): A Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Visually Enhanced Education About Prostate Cancer
Visually Enhanced Education About Prostate Cancer (VEEP-C): A Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Endoscopic Ultrasound Guided Liver Biopsy
Endoscopic Ultrasound Guided Liver Biopsy Using a 22 Gauge Fine Needle Biopsy Needle.
Status: Enrolling
Updated:  12/31/1969
Center for Interventional Endoscopy - Florida Hospital
mi
from
Orlando, FL
Endoscopic Ultrasound Guided Liver Biopsy
Endoscopic Ultrasound Guided Liver Biopsy Using a 22 Gauge Fine Needle Biopsy Needle.
Status: Enrolling
Updated: 12/31/1969
Center for Interventional Endoscopy - Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Barretos,
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Barretos,
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Vallejo
mi
from
Vallejo, CA
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Vallejo
mi
from
Vallejo, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Anne Arundel Health System Research Instit-Annapolis Oncology Ctr
mi
from
Annapolis, MD
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Anne Arundel Health System Research Instit-Annapolis Oncology Ctr
mi
from
Annapolis, MD
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
Status: Enrolling
Updated:  12/31/1969
University Cancer & Blood Center, LLC; Research
mi
from
Athens, GA
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
Status: Enrolling
Updated: 12/31/1969
University Cancer & Blood Center, LLC; Research
mi
from
Athens, GA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Montreal,
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Montreal,
Click here to add this to my saved trials
TAS-102 in Treating Advanced Biliary Tract Cancers
Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract Cancers
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
TAS-102 in Treating Advanced Biliary Tract Cancers
Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract Cancers
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
TAS-102 in Treating Advanced Biliary Tract Cancers
Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract Cancers
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
TAS-102 in Treating Advanced Biliary Tract Cancers
Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract Cancers
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial
Status: Enrolling
Updated:  12/31/1969
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial
Status: Enrolling
Updated: 12/31/1969
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR)
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR)
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
Evaluation of the Effect of Exisulind on the Duration of the "Off-Treatment" Interval on Patients With Biochemical Relapse of Prostate Cancer Who Are Treated With Intermittent Androgen Suppression (ADT)
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
Evaluation of the Effect of Exisulind on the Duration of the "Off-Treatment" Interval on Patients With Biochemical Relapse of Prostate Cancer Who Are Treated With Intermittent Androgen Suppression (ADT)
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle; A Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle; A Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
Status: Enrolling
Updated:  12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
Status: Enrolling
Updated: 12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
University of Chicago /ID# 169231
mi
from
Chicago, IL
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
University of Chicago /ID# 169231
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Washington University School /ID# 169177
mi
from
Saint Louis, MO
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Washington University School /ID# 169177
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering /ID# 201016
mi
from
New York, NY
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering /ID# 201016
mi
from
New York, NY
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center Research /ID# 168756
mi
from
Canton, OH
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center Research /ID# 168756
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Oklahoma University /ID# 200937
mi
from
Oklahoma City, OK
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Oklahoma University /ID# 200937
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233
mi
from
Nashville, TN
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Baylor University /ID# 169860
mi
from
Houston, TX
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Baylor University /ID# 169860
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
MD Anderson Cancer Center /ID# 169232
mi
from
Houston, TX
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
MD Anderson Cancer Center /ID# 169232
mi
from
Houston, TX
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
Bellevue Hospital Center
mi
from
New York, NY
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
Bellevue Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas
Phase II Study of Pembrolizumab in Advanced Poorly-Differentiated and/or High-Grade Neuroendocrine Tumors/Carcinomas
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas
Phase II Study of Pembrolizumab in Advanced Poorly-Differentiated and/or High-Grade Neuroendocrine Tumors/Carcinomas
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Observation Versus Immediate Surgery of Low Risk Bladder Cancer
Observation Versus Immediate Surgery of Low Risk Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Observation Versus Immediate Surgery of Low Risk Bladder Cancer
Observation Versus Immediate Surgery of Low Risk Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer
1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated:  12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer
1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated: 12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer
Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer
Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer
Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated:  12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer
Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated: 12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy
A Single-Center Double Arm Single-Blinded Randomized Screening Clinical Trial to Evaluate the Use of Human Dehydrated Amnion/Chorion Membrane to Facilitate the Recovery of Renal Function Following Robotic Partial Nephrectomy
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy
A Single-Center Double Arm Single-Blinded Randomized Screening Clinical Trial to Evaluate the Use of Human Dehydrated Amnion/Chorion Membrane to Facilitate the Recovery of Renal Function Following Robotic Partial Nephrectomy
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
Status: Enrolling
Updated:  12/31/1969
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
Status: Enrolling
Updated: 12/31/1969
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors
Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors (NOURISH-T)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors
Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors (NOURISH-T)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors
Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors (NOURISH-T)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins All Children's Hospital
mi
from
Saint Petersburg, FL
Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors
Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors (NOURISH-T)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Status: Enrolling
Updated:  12/31/1969
Chan Soon-Shiong Institute for Medicine
mi
from
El Segundo, CA
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Status: Enrolling
Updated: 12/31/1969
Chan Soon-Shiong Institute for Medicine
mi
from
El Segundo, CA
Click here to add this to my saved trials